Results 151 to 160 of about 111,828 (202)
Some of the next articles are maybe not open access.
Plasminogen Activator Inhibitor-1
Current Medicinal Chemistry, 2004Plasminogen activator inhibitor-1 (PAI-1) is an important component of the plasminogen/plasmin system as it is the main inhibitor of tissue-type and urokinase-type plasminogen activator. Consequently, PAI-1 plays an important role in cardiovascular diseases (mainly through inhibition of t-PA) and in cell migration and tumor development (mainly through ...
Ann, Gils, Paul J, Declerck
openaire +2 more sources
Urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-1
Oncology Reports, 1997Tumor associated proteolysis is an essential mechanism in invasion and metastasis of cancer. The influence of the serine protease urokinase-like plasminogen activator (u-PA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) on the clinical prognosis of squamous carcinoma of the head and neck region (HNSCC) was evaluated. U-PA and PAI-1 levels
B, Wollenberg +4 more
openaire +2 more sources
Plasminogen activator inhibitor type 1 deficiency
Haemophilia, 2008Summary. Plasminogen activator inhibitor type 1 (PAI‐1) is an important component of the coagulation system that down‐regulates fibrinolysis in the circulation. Reduced PAI‐1 levels may result in increased fibrinolysis and an associated bleeding diathesis. Clear documentation of PAI‐1 deficiency as a cause of a bleeding disorder has been rare.
R, Mehta, A D, Shapiro
openaire +2 more sources
Plasminogen Activator Inhibitor-1 in Aging
Seminars in Thrombosis and Hemostasis, 2014Plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. This induction of PAI-1 may play an important role in the pathology of these diseases as PAI-1 can regulate the dissolution of fibrin and also inhibit ...
Koji, Yamamoto +2 more
openaire +2 more sources
Plasminogen Activator Inhibitor-1 and Restenosis
Current Drug Targets, 2007Despite the introduction of drug-eluting stents restenosis remains an important clinical problem. In this review we examine the role of plasminogen activator inhibitor-1 (PAI-1) in controlling restenosis after balloon angioplasty and stent implantation.
Nadish, Garg, William P, Fay
openaire +2 more sources
Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992We have shown that the urokinase (UK) kringle domain contains a high-affinity plasminogen activator inhibitor-1 (PAI-1) binding site, responsible for the 10-fold faster complex formation between UK and PAI-1 than between PAI-1 and low-molecular-weight urokinase (LMWUK).
J, Mimuro +4 more
openaire +2 more sources
Plasminogen Activator Inhibitor 1 and Plasminogen Activator Inhibitor 2 in Various Disease States
Thrombosis and Haemostasis, 1988SummaryThe association of increased PA-inhibitor (PAI) activity and of PAI-1 and PAI-2 antigen levels with different pathological conditions was studied in a collective of over 300 patients. PAI-1 and PAI-2 levels were measured by specific radioimmunoassays.
E K, Kruithof, A, Gudinchet, F, Bachmann
openaire +2 more sources
Plasminogen Activator Inhibitor-1
2008Fibrinolysis, the dissolution of fibrin clots, is an integral component of the hemostatic system that involves the concerted action of a complex system of zymogens, activators, and inhibitors [1]. Plasmin, the primary protease of the fibrinolysic system, digests fibrin, thereby converting insoluble clot to soluble fibrin degradation products.
Daniel T. Eitzman +2 more
openaire +1 more source